161 related articles for article (PubMed ID: 30241991)
1. Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Owattanapanich W; Owattanapanich N; Kungwankiattichai S; Ungprasert P; Ruchutrakool T
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):814-821.e3. PubMed ID: 30241991
[TBL] [Abstract][Full Text] [Related]
2. Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.
Sekine L; Morais VD; Lima KM; Onsten TG; Ziegelmann PK; Ribeiro RA
Hematol Oncol; 2015 Dec; 33(4):212-9. PubMed ID: 25363800
[TBL] [Abstract][Full Text] [Related]
3. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients].
Sun AN; Tian XP; Cao XS; Ouyang J; Gu J; Xu KL; Yu K; Zeng QS; Sun ZM; Chen GA; Gao SJ; Zhou J; Wang JH; Yang LH; Luo JM; Zhang M; Guo XH; Wang XM; Zhang X; Shi KQ; Sun H; Ding XM; Hu JD; Zheng RJ; Zhao HG; Hou M; Wang X; Chen FP; Zhu Y; Liu H; Huang DP; Liao AJ; Ma LM; Su LP; Liu L; Zhou ZP; Huang XB; Sun XM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1017-1023. PubMed ID: 29365393
[No Abstract] [Full Text] [Related]
6. Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Adige S; Lapidus RG; Carter-Cooper BA; Duffy A; Patzke C; Law JY; Baer MR; Ambulos NP; Zou Y; Bentzen SM; Emadi A
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1105-1112. PubMed ID: 30968179
[TBL] [Abstract][Full Text] [Related]
7. Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
Choi EJ; Lee JH; Lee JH; Park HS; Ko SH; Hur EH; Moon J; Goo BK; Kim Y; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Leuk Res; 2018 May; 68():51-56. PubMed ID: 29544132
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
9. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H
J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249
[TBL] [Abstract][Full Text] [Related]
10. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
11. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
[TBL] [Abstract][Full Text] [Related]
12. Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Shen Y; Chen J; Liu Y; Wu D
Chemotherapy; 2014; 60(5-6):368-74. PubMed ID: 26496511
[TBL] [Abstract][Full Text] [Related]
13. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S; Miyawaki S; Fujita H; Kiyoi H; Shinagawa K; Usui N; Okumura H; Miyamura K; Nakaseko C; Miyazaki Y; Fujieda A; Nagai T; Yamane T; Taniwaki M; Takahashi M; Yagasaki F; Kimura Y; Asou N; Sakamaki H; Handa H; Honda S; Ohnishi K; Naoe T; Ohno R
Blood; 2011 Feb; 117(8):2358-65. PubMed ID: 20693429
[TBL] [Abstract][Full Text] [Related]
15. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Mandelli F; Petti MC; Ardia A; Di Pietro N; Di Raimondo F; Ganzina F; Falconi E; Geraci E; Ladogana S; Latagliata R
Eur J Cancer; 1991; 27(6):750-5. PubMed ID: 1829918
[TBL] [Abstract][Full Text] [Related]
16. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
Lee JH; Kim H; Joo YD; Lee WS; Bae SH; Zang DY; Kwon J; Kim MK; Lee J; Lee GW; Lee JH; Choi Y; Kim DY; Hur EH; Lim SN; Lee SM; Ryoo HM; Kim HJ; Hyun MS; Lee KH;
J Clin Oncol; 2017 Aug; 35(24):2754-2763. PubMed ID: 28632487
[TBL] [Abstract][Full Text] [Related]
17. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
18. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
19. Daunorubicin 90 mg/m
Portugal R; Lyrio R; Loureiro M; Urago K; Bard J; Borchardt A; Garnica M; Nucci M
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):527-531. PubMed ID: 28842139
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]